RADIATION SICKNESS AND ITS CONTROL WITH THIETHYLPERAZINE (TORECAN): A PRELIMINARY EVALUATION

Journal Article · Sat Apr 27 04:00:00 EST 1963 · Med. J. Australia

OSTI ID:4160126

Donovan, J

Thiethylperazine was tested cliniically on the grounds that it is a potent antiemetic without significant tranquillizing properties. The 77 patients tested were treated with comventional radiotherapy, a typical dose for carcinoma of the breast being 4000 to 4500 r. Thiethylperazine maleate was used in a standard dosage of one tablet three times a day, in most cases as soom as the patient developed symptoms but in a few cases for prophylaxis when very large abdominal fields were irradiated. Of 31 patients with carcimoma of the breast, 22 obtained complete relief from nausea and vomiting and an additional six obtained partial relief; treatment was ineffective in only three cases. Patients with abdominial and pelvic neoplasms were less responsive to treatment, only about half experimencing complete relief. Altogether, complete or partial relief was obtained by 92% and the treatment was ineffective in 8% of cases. Thiethylperazine was tolerated well and most patients experienced no side-effects. It is concluded that thiethlperazine is in extremely effective drug in the management of radiation sickness, and is possibly the most effective drug now available. (BBB)

• Research Organization: Royal Prince Alfred Hospital, Sydney
• NSA Number: NSA-18-005145
• OSTI ID: 4160126
• Journal Information: Med. J. Australia, Journal Name: Med. J. Australia Vol. Vol: 1
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

BIOLOGY AND MEDICINE
CANCER
DISTRIBUTION
DRUGS
EFFICIENCY
GLANDS
MAMMARY GLANDS
MAN
MEDICINE
NAUSEA
QUANTITY RATIO
RADIATION DOSES
RADIATION SICKNESS
RADIOTHERAPY
SENSITIVITY
TESTING
TRANQUILLIZERS
VARIATIONS
VOMITING